A listing of Virus medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.
The purpose of this study is to evaluate the safety, tolerability, and effectiveness of TAF against the Hepatitis B Virus in all of the enrolled adolescent subjects.
Related donor Epstein-Barr Virus (EBV) specific cytotoxic T cells (CTLs) manufactured withhe Miltenyi CliniMACS Prodigy Cytokine Capture System will be administered in children,dolescents and young adults with refractory EBV infection post Allogeneic Hematopoietic Stem Cell Transplantation (AlloHSCT), with primary immunodeficiencies (PID) or post solid organ. Funding Source: FDA OOPD
The purpose of this registry is to periodically ask participants questions related to their and their family’s wellbeing as well as notify participants of other COVID-19 related research studies taking place at Indiana University and its partnering institutions.
The purpose of this study is to understand what the symptoms of patients that get COVID-19 are like at first and then how these symptoms change with time. We hope that by understanding these specific symptoms that patients with COVID-19 can be identified earlier and potentially treated earlier as well.
The purpose of this study is to evaluate the effect of the pandemic we are going through has in our patients and investigate whether it causes them any issues long-term.
The purpose of this research is to collect biospecimens and information about you for research involving unspecified laboratory experiments in order to study how blood cells and serum/plasma from healthy people interact and respond to coronaviruses, including SARS-CoV2, which is responsible for COVID-19.
BK cytotoxic T cells (CTLs) manufactured with the Miltenyi CliniMACS Prodigy Cytokine Captureystem will be safe and effective in decreasing specific viral load in children, adolescentsd young adults (CAYA) with refractory BK infection post Allogeneic Hematopoietic Stem Cell Transplantation (AlloHSCT) or with primary immunodeficiencies (PID).
CMV cytotoxic T cells (CTLs) manufactured with the Miltenyi CliniMACS Prodigy Cytokine Capture System will be administered in children, adolescents and young adults (CAYA) withy cytomegalovirus (CMV) infection post Allogeneic Hematopoietic Stem Cell Transplantation (AlloHSCT), with primary immunodeficiencies (PID) or post solid organ. Funding Source: FDA OOPD